Replies to post #28 on Alexion Pharmaceuticals, Inc. (ALXN)

[stocktrader001]

Relatively High EBITDA Growth Detected in Shares of Cepheid in the Biotechnology Industry (CPHD, GHDX, GENZ, ALXN, UTHR)

Feb 14, 2011 (SmarTrend(R) News Watch via COMTEX) -- Below are the five companies in the Biotechnology industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Cepheid (CPHD) has the highest with EBITDA Growth of 214.2%; Genomic Health (GHDX) is next with EBITDA Growth of 181.9%; and Genzyme (GENZ) has the next highest with EBITDA Growth of 179.8%.

Alexion Pharmaceuticals (ALXN) follows with EBITDA Growth of 141.3% and United Therapeutics (UTHR) rounds out the group with EBITDA Growth of 97.9%.

SmarTrend currently has shares of Alexion Pharmaceuticals in an Uptrend and issued the Uptrend alert on June 18, 2010 at $54.41. The stock has risen 65.5% since the Uptrend alert was issued.

http://www.investors.com/NewsAndAnalysis/Newsfeed/Article/126654463/201102140631/Relatively-High-EBITDA-Growth-Detected-in-Shares-of-Cepheid-in-the.aspx